Filing Flows › Tvardi Therapeutics (TVRD) › Q1 2025 › vs Q4 2024
Tvardi Therapeutics (TVRD) Q1 2025 vs Q4 2024 (quarter over quarter)
Tvardi Therapeutics's revenue rose $1.1M (+77%) from $1.5M in Q4 2024 to $2.6M in Q1 2025.
Tvardi Therapeutics, Q1 2025: revenue $2.6M (+20% year over year), operating margin -92.9%, net loss $4.9M, operating cash flow −$4.7M. The chart draws each line against Q4 2024, the increases inside each band.
Every line
| Line | Q1 2025 | Q4 2024 | Change | % |
|---|---|---|---|---|
| Revenue | $2.6M | $1.5M | $1.1M | +77% |
| Net loss | $4.9M | $7.7M | −$2.8M | -36% |
| Costs & expenses | $7.5M | $9.5M | −$2.1M | -22% |
| Operating costs | $5.0M | $6.9M | −$1.9M | -28% |
| Interest & other, net | $2.5M | $2.7M | −$134K | -5% |
| Operating cash sources | $6.1M | $6.4M | −$279K | -4% |
| Share-based compensation | $1.4M | $2.4M | −$928K | -39% |
| Cash used in operations | $4.7M | $4.0M | $649K | +16% |
| Net loss absorbed | $4.9M | $7.7M | −$2.8M | -36% |
| Working capital & other | $1.2M | −$1.3M | $2.5M | — |
Questions
How much did Tvardi Therapeutics's revenue grow quarter over quarter in Q1 2025?
Tvardi Therapeutics's revenue rose $1.1M (+77%) from $1.5M in Q4 2024 to $2.6M in Q1 2025.